Hydrocortisone Valerate Ointment is Glenmark’s first granted competitive generic therapy(CGT) product approved by the FDA.
Mumbai: Pharma major Glenmark Pharma said that Glenmark Pharmaceuticals Inc., US has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Hydrocortisone Valerate Ointment USP, 0.2 pc, a generic version of Westcort Ointment, 0.2 pc, of Sun Pharmaceutical Industries, Inc.
The company has been granted a competitive generic therapy (CGT) designation for Hydrocortisone Valerate Ointment USP, 0.2 pc, therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialisation, Glenmark said in a filing with BSE.
This medication is used to treat a variety of skin conditions such as eczema, dermatitis, allergies, rash. Hydrocortisone valerate reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a medium-strength corticosteroid.
This is Glenmark’s first granted CGT product approved by the FDA.
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. The company went public in India in 1999 and used some of the proceeds to build its first research facility.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019